Pulmonary Embolism Clinical Trial
Official title:
A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
| Status | Completed |
| Enrollment | 961 |
| Est. completion date | September 2006 |
| Est. primary completion date | September 2006 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 35 Years and older |
| Eligibility |
Inclusion Criteria: - Women must be unable to have children. - Will have a total knee replacement. Exclusion Criteria: - Allergic to any X-ray dye. - Allergies or reactions to warfarin or coumadin. - Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT). - On anticoagulation therapy. - Renal impairment. - Participated in any clinical trial in the past 30 days. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Australia | GSK Investigational Site | Box Hill | Victoria |
| Australia | GSK Investigational Site | Camperdown | New South Wales |
| Australia | GSK Investigational Site | Clayton | Victoria |
| Australia | GSK Investigational Site | Geelong | Victoria |
| Australia | GSK Investigational Site | Southport | Queensland |
| Australia | GSK Investigational Site | Windsor | Victoria |
| Brazil | GSK Investigational Site | Porto Alegre | Rio Grande Do Sul |
| Brazil | GSK Investigational Site | Porto Alegre | Rio Grande Do Sul |
| Canada | GSK Investigational Site | Ajax | Ontario |
| Canada | GSK Investigational Site | Charlottetown | Prince Edward Island |
| Canada | GSK Investigational Site | Don Mills | Ontario |
| Canada | GSK Investigational Site | Montreal | Quebec |
| Canada | GSK Investigational Site | Newmarket | Ontario |
| Canada | GSK Investigational Site | North York | Ontario |
| Canada | GSK Investigational Site | Oshawa | Ontario |
| Canada | GSK Investigational Site | Québec | Quebec |
| Canada | GSK Investigational Site | Sainte Jerome | Quebec |
| Canada | GSK Investigational Site | Scarborough | Ontario |
| Canada | GSK Investigational Site | Waterloo | Ontario |
| Canada | GSK Investigational Site | Winnipeg | Manitoba |
| India | GSK Investigational Site | Chennai | |
| India | GSK Investigational Site | Secunderabad | |
| Israel | GSK Investigational Site | Tel-Aviv | |
| Latvia | GSK Investigational Site | Riga | |
| Latvia | GSK Investigational Site | Riga | |
| Lithuania | GSK Investigational Site | Klaipeda | |
| Lithuania | GSK Investigational Site | Vilnius | |
| Poland | GSK Investigational Site | Krakow | |
| Poland | GSK Investigational Site | Wroclaw | |
| Russian Federation | GSK Investigational Site | Irkutsk | |
| Russian Federation | GSK Investigational Site | Kurgan | |
| Russian Federation | GSK Investigational Site | Moscow | |
| Russian Federation | GSK Investigational Site | Mosocow | |
| Russian Federation | GSK Investigational Site | Mosocow | |
| South Africa | GSK Investigational Site | Centurion | |
| South Africa | GSK Investigational Site | Pretoria | |
| South Africa | GSK Investigational Site | Pretoria | Gauteng |
| Ukraine | GSK Investigational Site | Cherkasy | |
| Ukraine | GSK Investigational Site | Dnepropetrovsk | |
| Ukraine | GSK Investigational Site | Kyiv | |
| Ukraine | GSK Investigational Site | Kyiv | |
| Ukraine | GSK Investigational Site | Vinnitsa | |
| United Kingdom | GSK Investigational Site | Birmingham | West Midlands |
| United Kingdom | GSK Investigational Site | Bournmouth | |
| United Kingdom | GSK Investigational Site | Fife | |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | Wigan | |
| United States | GSK Investigational Site | Allentown | Pennsylvania |
| United States | GSK Investigational Site | Altoona | Pennsylvania |
| United States | GSK Investigational Site | Baltimore | Maryland |
| United States | GSK Investigational Site | Baton Rouge | Louisiana |
| United States | GSK Investigational Site | Birmingham | Alabama |
| United States | GSK Investigational Site | Boise | Idaho |
| United States | GSK Investigational Site | Camp Hill | Pennsylvania |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Clearwater | Florida |
| United States | GSK Investigational Site | Dallas | Texas |
| United States | GSK Investigational Site | Decatur | Georgia |
| United States | GSK Investigational Site | Deland | Florida |
| United States | GSK Investigational Site | Hershey | Pennsylvania |
| United States | GSK Investigational Site | Lexington | Kentucky |
| United States | GSK Investigational Site | Little Rock | Arkansas |
| United States | GSK Investigational Site | Lubbock | Texas |
| United States | GSK Investigational Site | Marshfield | Wisconsin |
| United States | GSK Investigational Site | Mineola | New York |
| United States | GSK Investigational Site | Mobile | Alabama |
| United States | GSK Investigational Site | Norfolk | Virginia |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Phoenix | Arizona |
| United States | GSK Investigational Site | Richmond | Virginia |
| United States | GSK Investigational Site | Sacramento | California |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | Sarasota | Florida |
| United States | GSK Investigational Site | Sarsota | Florida |
| United States | GSK Investigational Site | St. Petersburg | Florida |
| United States | GSK Investigational Site | Torrance | California |
| United States | GSK Investigational Site | Warren | Michigan |
| United States | GSK Investigational Site | Yuba City | California |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United States, Australia, Brazil, Canada, India, Israel, Latvia, Lithuania, Poland, Russian Federation, South Africa, Ukraine, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Total venous thromboembolism (VTE) event rate after 8 - 12 days of dosing. | 12 Days | ||
| Secondary | Relative risk of VTE at Day 10. VTE event rate for odiparcil at Day 10. Pharmacodynamic effect as measured by anti-IIa activity at Days 1, 3, 5 and 10. Measurements of LFTs and major bleeding anytime during the trial. | 10 Days |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
| Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
| Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
| Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
| Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
| Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
| Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
| Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
| Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
| Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
| Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
| Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
| Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
| Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
| Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|